RADIOPHARMACOLOGY 

The Quarterly Journal of Nuclear Medicine 2001 June;45(2):183-8

Copyright © 2009 EDIZIONI MINERVA MEDICA

language: English

PET imaging of hypoxia

Lewis J. S., Welch M. J.

From the Mallinckrodt Institute of Radiology Washington University School of Medicine St. Louis, MO, USA

Hypoxia in ­tumors has ­been ­related to ­poor ­response to con­ven­tional ther­a­pies. ­This ­paper ­will dis­cuss the ­methods, ­both inva­sive and non-inva­sive, ­used to deter­mine ­hypoxia ­levels ­within ­tumors. PET ­imaging ­with two ­lead com­pounds 18F-flu­o­ro­mis­o­nid­a­zole (18­FMISO) and Cu(II)-dia­cetyl-bis(N4-meth­yl­thi­o­sem­i­car­ba­zone (Cu-­ATSM) and ­their rel­a­tive effec­tive­ness in delin­eating ­hypoxic ­regions ­will be dis­cussed. The advan­tages of Cu-­ATSM-PET ­over ­existing ­imaging ­agents ­will be dis­cussed ­along ­with its poten­tial appli­ca­tion as a ­direct- and/or sur­ro­gate ­marker for the deter­mi­na­tion of onco­log­ical ­hypoxia in ­vivo.